Drug updated on 9/5/2024
| Dosage Form | Injection (intramuscular/subcutaneous; 0.5 mL) |
| Drug Class | Vaccines |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).
Latest News
Summary
- Pneumovax 23 (pneumococcal vaccine polyvalent) is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).
- This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
- PCV13: Demonstrated 75% efficacy against PCV13-type invasive pneumococcal disease (IPD) and 45% efficacy against PCV13-type pneumococcal pneumonia (PP) in one randomized controlled trial (RCT); observational studies showed effectiveness against PCV13-type IPD ranging from 47% to 68% and against PCV13-type PP ranging from 38% to 68%.
- PPSV23: Pooled effectiveness was 45% (95% CI: 37%-51%) against PPSV23-type IPD (nine studies) and 18% (95% CI: -4%-35%) against PPSV23-type PP.
- Dialysis Patients: No serious adverse effects reported.
- PLWH: Immunogenicity improved with higher CD4 counts; no long-term safety data provided.
- General Safety: Specific safety outcomes were not detailed in the studies. No specific safety concerns or adverse effects were noted in the studies for any specific population types or subgroups.
- There is no population or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pneumovax (pneumococcal vaccine polyvalent) Prescribing Information. | 2023 | Merck Sharp & Dohme LLC, Rahway, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Pneumococcal vaccination - a literature review and practice guideline update. | 2022 | Pharmacotherapy |
| Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)—part 2: inactivated vaccines. | 2021 | Journal of the Canadian Association of Gastroenterology |
| Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices. | 2019 | US Department of Health and Human Services/Centers for Disease Control and Prevention |
| 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. | 2019 | Annals of Rheumatic Disease |
| Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. | 2019 | European Journal of Clinical Microbiology & Infectious Diseases |